ReviewDrugs2015
Disease modification in epilepsy: from animal models to clinical applications.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Identification of EEG features during status epilepticus for prediction of emergent epilepsy phenotype in the mouse intra-amygdala kainic acid model using supervised learning.IBRO neuroscience reports · 2026Article
- Diverse species of animal models in epilepsy research: Progress and perspectives.Zoological research · 2025Review
- Alzheimer's disease-associated genotypes differentially influence chronic evoked seizure outcomes and antiseizure medicine efficacy in aged mice.Journal of Alzheimer's disease : JAD · 2025Article
- Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis.Expert opinion on drug discovery · 2024Review
- Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy.eLife · 2023Article
- Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.Experimental neurology · 2023Review
- Benchmarking the proteomic profile of animal models of mesial temporal epilepsy.Annals of clinical and translational neurology · 2022Article
- Circulating MicroRNAs From Plasma Small Extracellular Vesicles as Potential Diagnostic Biomarkers in Pediatric Epilepsy and Drug-Resistant Epilepsy.Frontiers in molecular neuroscience · 2022Article
- Development of an antiepileptogenesis drug screening platform: Effects of everolimus and phenobarbital.Epilepsia · 2021Article
- Diurnal burden of spontaneous seizures in early epileptogenesis in the post-kainic acid rat model of epilepsy.Epilepsia open · 2021Article
- Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines.Epilepsy currents · 2020Article
- Harmonization of the pipeline for seizure detection to phenotype post-traumatic epilepsy in a preclinical multicenter study on post-traumatic epileptogenesis.Epilepsy research · 2019Article
- Retrieval-Induced Forgetting in a Pentylenetetrazole-Induced Epilepsy Model in the Rat.Brain sciences · 2018Article
- Brief history of anti-seizure drug development.Epilepsia open · 2018Article
- The Challenge of microRNA as a Biomarker of Epilepsy.Current neuropharmacology · 2018Review
- Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy.Pharmacology & therapeutics · 2017Review
- WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?Epilepsia · 2017Review
- Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy.Epilepsia open · 2016Article
- Article
- Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.Epilepsia · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several relevant animal models of epileptogenesis and biomarkers have emerged for evaluating the antiepileptogenic potential of an investigational drug. Although several promising candidate compounds and approaches have been identified in these preclinical models, no treatment has yet successfully navigated the path from preclinical efficacy to clinical validation. Until such an agent can move from preclinical proof of concept to clinical success, the need remains to continually develop and optimize preclinical models and clinical trial design in an effort to guide potential clinical investigations. This review describes several available models of disease modification and/or epileptogenesis, preclinical studies in these models and potential biomarkers useful for evaluating the efficacy of a potential therapeutic agent in the preclinical setting. The results that emerge from such efforts may then guide the clinical evaluation of a candidate compound. This review discusses some of the known limitations and hurdles to moving compounds found effective in these models to clinical practice, in the hope that knowledge of this information will facilitate the design and conduct of clinical studies and effectively facilitate the identification of a first-in-class disease-modifying or antiepileptogenic agent.
Indexed as
Identifiers
25925798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.